Skip to main content

2010 New Drug Approvals - Pt. XIV - Dabigatran etexilate (Pradaxa)



ATC Code: B01AE07

Dabigatran etexilate has been approved by the FDA on October 19th 2010. Dabigatran etexilate (also known as BIBR-1048 for Dabigatran etexilate and BIBR-953 for Dabigatran) is approved for the treatment of patients with atrial fibrillation at risk of embolism or stroke. Dabigatran etexilate is a first-in-class (for the US) oral drug preventing blood clotting and stroke by direct inhibition of thrombin and is marketed under the trade name Pradaxa in Europe and the US, and Pradax in certain other territories. In Europe, an earlier oral direct thrombin inhibitor Xemelagatran (trademark:Exanta trademark:Exarta also known as H376/95) was approved, but subsequently was withdrawn due to commercial and perceived safety issues.

The formation of blood clots in the circulation can cause embolism or stroke (or CVA) if other risk factors are present.  Depending on the number of risk factors, the risk of suffering a stroke increases up to 7-fold in patients with atrial fibrillation. Patients with atrial fibrillation are therefore often treated with the anticoagulant warfarin (ChEMBL: 494165) to prevent the formation of blood clots, Warfarin is a drug with a poor therapeutic index, and also shows substantial intra-patient variability due to underlying genetic differences, with subsequent required regular patient monitoring.


Dabigatran etexilate is converted to the active drug Dabigatran. It inhibits blood clotting through direct inhibition of thrombin (Uniprot: P00734) and has a larger therapeutic window than warfarin (which is an irreversible inhibitor of vitamin K epoxide reductase). Thrombin is a key serine protease in the blood clotting cascade, activating coagulation factors Factor V, Factor VIII, Factor XI and Factor XIII as well as cleaving fibrinogen and thus transforming it to the blood clot forming fibrin (also known as Factor Ia) (Uniprot: P02679). There are many known structures of thrombin, both in prothrombin and mature thrombin forms (for example see PDBe:2bvs).

Thrombin is a trypsin-like serine proteinase (Pfam:PF00089), and cleaves after arginine (and lysine) residues at the P1 position in substrates; Dabigatran is a substrate mimic (a peptidomimetic), with the phenylamidine mimicking the arginine sidechain.

Upon absorpotion, Dabigatran etexilate is readily metabolized to the active drug Dabigatran by ester hydrolysis at two distinct positions (therefore Dabigatran is dosed as a double prodrug). The charged groups of Dabigatran (the amidine and carboxylic acid) are poorly absorbed across membranes, and therefor the lipophilic ester and carbamate are added to mask these groups during oral dosing and absorption. Dabigatran is further metabolized to four different acyl glucuronides which are equally active as thrombin inhibitors. The absolute oral biovailability of Dabigatran (dosed as the prodrug) is 3-7%. The fraction of dabigatran bound to plasma proteins (ppb) is ~35% and volume of distribution (Vd) is 50-70L, clearance is primarily renal with a half-life (t1/2) of 12-14 hours.

Dabigatran etexilate is recommended for twice daily administration of 300mg (in two 150mg doses).





SMILES:
CCCCCCOC(=O)N=C(N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)
N(CCC(=O)OCC)c4ccccn4)cc1
 
InChI:
1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-
13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-
31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-
21,23H2,1-3H3,(H2,35,39,44) 
 
Dabigatran etexilate is marketed under the trade name Pradaxa by
Boehringer Ingelheim.
 
Full prescribing information can be found here. 
 

Comments

Popular posts from this blog

UniChem 2.0

UniChem new beta interface and web services We are excited to announce that our UniChem beta site will become the default one on the 11th of May. The new system will allow us to better maintain UniChem and to bring new functionality in a more sustainable way. The current interface and web services will still be reachable for a period of time at https://www.ebi.ac.uk/unichem/legacy . In addition to it, the most popular legacy REST endpoints will also remain implemented in the new web services: https://www.ebi.ac.uk/unichem/api/docs#/Legacy Some downtime is expected during the swap.  What's new? UniChem’s current API and web application is implemented with a framework version that’s not maintained and the cost of updating it surpasses the cost of rebuilding it. In order to improve stability, security, and support the implementation and fast delivery of new features, we have decided to revamp our user-facing systems using the latest version of widely used and maintained frameworks, i

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

ChEMBL 30 released

  We are pleased to announce the release of ChEMBL 30. This version of the database, prepared on 22/02/2022 contains: 2,786,911 compound records 2,157,379 compounds (of which 2,136,187 have mol files) 19,286,751 activities 1,458,215 assays 14,855 targets 84,092 documents Data can be downloaded from the ChEMBL FTP site: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_30/ Please see ChEMBL_30 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_30/chembl_30_release_notes.txt New Deposited Datasets EUbOPEN Chemogenomic Library (src_id = 55, ChEMBL Document ID CHEMBL4689842):   The EUbOPEN consortium is an Innovative Medicines Initiative (IMI) funded project to enable and unlock biology in the open. The aims of the project are to assemble an open access chemogenomic library comprising about 5,000 well annotated compounds covering roughly 1,000 different proteins, to synthesize at least

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra